{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:44:26Z","timestamp":1792100666841,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research","doi-asserted-by":"publisher","award":["KFS-5486-02-2022"],"award-info":[{"award-number":["KFS-5486-02-2022"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["MERiC"],"award-info":[{"award-number":["MERiC"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.celrep.2026.117895","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:11:32Z","timestamp":1787577092000},"page":"117895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatocellular carcinoma organoids enable drug discovery and combination therapy across heterogeneous tumors"],"prefix":"10.1016","volume":"45","author":[{"given":"Sandro","family":"Nuciforo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Blukacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Heusler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tijmen H.","family":"Booij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Trulsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyana","family":"Boldanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Ketterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias S.","family":"Matter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Stirnimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7523-4894","authenticated-orcid":false,"given":"Markus H.","family":"Heim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.117895_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2026.117895_bib2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.cgh.2023.01.039","article-title":"Breakthroughs in Hepatocellular Carcinoma Therapies","volume":"21","author":"Singal","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.celrep.2026.117895_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)","volume":"161","author":"Haber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2026.117895_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41417-024-00764-w","article-title":"Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications","volume":"31","author":"Safri","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.celrep.2026.117895_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.117895_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.celrep.2026.117895_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.celrep.2026.117895_bib8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","article-title":"Phenotypic drug discovery: recent successes, lessons learned and new directions","volume":"21","author":"Vincent","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.celrep.2026.117895_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tips.2024.06.001","article-title":"Innovating cancer drug discovery with refined phenotypic screens","volume":"45","author":"Wang","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.celrep.2026.117895_bib10","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","article-title":"Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery","volume":"24","author":"Weeber","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117895_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","article-title":"Patient-derived organoids as a predictive biomarker for treatment response in cancer patients","volume":"5","author":"Wensink","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.celrep.2026.117895_bib12","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.117895_bib13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.celrep.2018.07.001","article-title":"Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies","volume":"24","author":"Nuciforo","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.117895_bib14","article-title":"Organoids to model liver disease","volume":"3","author":"Nuciforo","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.celrep.2026.117895_bib15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccell.2022.02.001","article-title":"Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions","volume":"40","author":"van Tienderen","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117895_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2026.117895_bib17","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117895_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nbt1186","article-title":"Statistical practice in high-throughput screening data analysis","volume":"24","author":"Malo","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.celrep.2026.117895_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.celrep.2026.117895_bib20","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.ejca.2004.02.027","article-title":"Systemic therapy for advanced hepatocellular carcinoma: a review","volume":"40","author":"Nowak","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117895_bib21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2026.117895_bib22","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","article-title":"A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors","volume":"18","author":"Mross","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117895_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The Toxicity of Poisons Applied Jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"10.1016\/j.celrep.2026.117895_bib24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent Drug Action in Combination Therapy: Implications for Precision Oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117895_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.celrep.2026.117895_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cell.2014.11.050","article-title":"Long-term culture of genome-stable bipotent stem cells from adult human liver","volume":"160","author":"Huch","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117895_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.30802\/AALAS-JAALAS-20-000020","article-title":"Reference Values for Hematology, Plasma Biochemistry, Bone Marrow Cytology and Bone Histology of NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)\/SzJ Immunodeficient Mice","volume":"60","author":"Layssol-Lamour","year":"2021","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"10.1016\/j.celrep.2026.117895_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg3358","article-title":"Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology","volume":"15","author":"Ji","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2026.117895_bib29","article-title":"Integrated characterization of hepatobiliary tumor organoids provides a potential landscape of pharmacogenomic interactions","volume":"5","author":"Zhu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.celrep.2026.117895_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccell.2024.03.004","article-title":"Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117895_bib31","article-title":"Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer","volume":"7","author":"Wong","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.celrep.2026.117895_bib32","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/cam4.1517","article-title":"Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models","volume":"7","author":"Matsuki","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.celrep.2026.117895_bib33","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1078-0432.CCR-13-2620","article-title":"Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET","volume":"20","author":"Xiang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117895_bib34","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.apsb.2022.09.010","article-title":"Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine","volume":"13","author":"Lee","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.celrep.2026.117895_bib35","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bjc.2014.431","article-title":"In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells","volume":"111","author":"Jiang","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2026.117895_bib36","doi-asserted-by":"crossref","first-page":"19579","DOI":"10.1073\/pnas.0809763105","article-title":"Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117895_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2026.117895_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108694","article-title":"A multicenter phase I\/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia","volume":"9","author":"Schimmer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2026.117895_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.toxicon.2018.11.429","article-title":"A review of cardiac glycosides: Structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential","volume":"158","author":"Botelho","year":"2019","journal-title":"Toxicon"},{"key":"10.1016\/j.celrep.2026.117895_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1124\/jpet.120.000486","article-title":"A p97\/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6","volume":"378","author":"Leinonen","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.celrep.2026.117895_bib41","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s10637-020-00915-4","article-title":"Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and\/or refractory multiple myeloma","volume":"38","author":"Rowinsky","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.celrep.2026.117895_bib42","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","article-title":"Effective drug combinations in breast, colon and pancreatic cancer cells","volume":"603","author":"Jaaks","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117895_bib43","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2159-8290.CD-23-0388","article-title":"Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations","volume":"14","author":"Bashi","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117895_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2024.11.006","article-title":"Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects","volume":"4","author":"Kaldjob-Heinrich","year":"2025","journal-title":"Gastro Hep Adv."},{"key":"10.1016\/j.celrep.2026.117895_bib45","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1038\/s41467-025-62934-0","article-title":"The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active","volume":"16","author":"Sequera","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117895_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn7824","article-title":"An ex vivo platform to guide drug combination treatment in relapsed\/refractory lymphoma","volume":"14","author":"Goh","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2026.117895_bib47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2026.117895_bib48","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2024.01.025","article-title":"Dual Inhibition of CDK4\/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs","volume":"166","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2026.117895_bib49","article-title":"Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma","volume":"7","author":"Koroki","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.celrep.2026.117895_bib50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2026.117895_bib51","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.117895_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.celrep.2026.117895_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0308-1","article-title":"Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers","volume":"51","author":"Fondevila","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.celrep.2026.117895_bib54","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2026.117895_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117895_bib56","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.cell.2018.11.013","article-title":"Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids","volume":"175","author":"Hu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117895_bib57","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41586-025-08861-y","article-title":"Generation of human adult hepatocyte organoids with metabolic functions","volume":"641","author":"Igarashi","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117895_bib58","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-025-09884-1","article-title":"Human assembloids recapitulate periportal liver tissue in vitro","volume":"650","author":"Yuan","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117895_bib59","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep4.1365","article-title":"Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors","volume":"3","author":"Blumer","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.celrep.2026.117895_bib60","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/nprot.2016.097","article-title":"Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation","volume":"11","author":"Broutier","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.celrep.2026.117895_bib61","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E","article-title":"Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies","volume":"7","author":"Edmondson","year":"1954","journal-title":"Cancer"},{"key":"10.1016\/j.celrep.2026.117895_bib62","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/2472555220942764","article-title":"Z' Does Not Need to Be > 0.5","volume":"25","author":"Bar","year":"2020","journal-title":"SLAS Discov."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726009733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726009733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:55:29Z","timestamp":1792097729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726009733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2211124726009733"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117895","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocellular carcinoma organoids enable drug discovery and combination therapy across heterogeneous tumors","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117895"}}